PacBio

216 articles with PacBio

• PacBio to Participate in the BofA Securities 2022 Healthcare Conference

  5/5/2022

  PacBio announced that it will be participating in the upcoming BofA Securities 2022 Healthcare Conference in Las Vegas, Nevada.

• PacBio Announces First Quarter 2022 Financial Results

  5/4/2022

  PacBio announced financial results for the quarter ended March 31, 2022.

• PacBio transforms access to the epigenome and streamlines workflows

  4/21/2022

  PacBio, a leading developer of high-quality, highly accurate sequencing solutions, announced the release of a transformative capability to detect DNA methylation using the Sequel IIe and Sequel II Systems.

• PacBio and Children’s Mercy Kansas City Expand Collaboration Taking a Multi-Omics Approach to Characterize Rare Disease

  4/21/2022

  PacBio announced an expanded research collaboration with Children’s Mercy Kansas City, one of the nation’s top pediatric medical systems, to use the multi-omics capabilities of PacBio’s Sequel IIe system in the study of genetic disease.

• PacBio to Report First Quarter 2022 Financial Results on May 4, 2022

  4/20/2022

  PacBio announced that it will hold its quarterly conference call to discuss its first quarter 2022 financial results on Wednesday, May 4, 2022, at 5:00 pm Eastern Time.

• 

  The Integral Role of HiFi Sequencing in Discovering What Makes Us Human

  4/18/2022

  Scientists recently announced the complete sequencing of the entire human genome. Biotech company PacBio - and HiFi sequencing - played a big role in this milestone.

• PacBio Enters Agricultural Industry Collaboration with Corteva Agriscience to Develop High-Throughput Plant, Pest and Microbial Sequencing

  4/4/2022

  PacBio, a leading provider of high-quality, highly accurate sequencing platforms, announced a new collaboration with global agriculture company, Corteva Agriscience, to develop custom, end-to-end workflows for plant, pest and microbial sequencing.

• HiFi Reads Enable Telomere-to-Telomere Consortium to Fill the Final Gaps in the Human Genome, Heralding a New Era of Research into Genetic Diseases and Human Biology

  3/31/2022

  PacBio, a leading provider of high-quality, highly accurate sequencing solutions, announced PacBio’s essential contribution to the completion of the first truly complete human reference genome.

• PacBio Opens European Headquarters in London

  3/23/2022

  PacBio, a leading developer of high-quality, highly accurate, sequencing platforms, announced the company’s expansion to better serve customers in the Europe, Middle East and Africa region.

• PacBio Grants Equity Incentive Award to New Employee - Feb 25, 2022

  2/25/2022

  PacBio announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 100,000 shares of PacBio common stock, and restricted stock units covering 50,000 shares of PacBio common stock, to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan effective on February 22, 2022.

• KK Women’s and Children’s Hospital and PacBio Collaborate in Asia’s First Study of Unexplained Neurodevelopmental Disorders

  2/16/2022

  KK Women’s and Children’s Hospital and PacBio, a leading provider of high-quality, highly accurate sequencing platforms, announced a collaboration to leverage PacBio technology in understanding the genetic causes of neurodevelopmental disorders.

• PacBio Announces Fourth Quarter and Fiscal Year 2021 Financial Results

  2/15/2022

  PacBio announced financial results for the quarter and fiscal year ended December 31, 2021.

• Pacific Biosciences of California, Inc. Third Quarter 2021 Financial Results Call

  10/19/2021

  Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its third quarter 2021 financial results on Tuesday, November 2, 2021, at 4:30pm Eastern Time.

• Pacific Biosciences Grants Equity Incentive Award to New Employee - Sep 24, 2021

  9/24/2021

  Pacific Biosciences of California, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 100,000 shares of Pacific Biosciences common stock, and restricted stock units covering 50,000 shares of Pacific Biosciences common stock, to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan effective on September 20, 2021.

• Pacific Biosciences Closes Acquisition of Omniome and Establishes San Diego Presence

  9/20/2021

  Pacific Biosciences of California, Inc. announced today the companies have closed the transaction under which Pacific Biosciences acquired Omniome.

• Pacific Biosciences of California, Inc. to Present at Upcoming Investor Conferences - Sep 03, 2021

  9/3/2021

  Pacific Biosciences of California, Inc. announced that its executives will be speaking at the following investor conferences.

• Pacific Biosciences of California, Inc. to Present at Upcoming Investor Conference - Aug 09, 2021

  8/9/2021

  Pacific Biosciences of California, Inc. announced that its executives will be speaking at the following investor conference:.

• Pacific Biosciences of California, Inc. Announces Second Quarter 2021 Financial Results

  8/3/2021

  Pacific Biosciences of California, Inc. announced financial results for the quarter ended June 30, 2021.

• Pacific Biosciences Signs Definitive Agreement to Acquire Omniome

  7/20/2021

  Pacific Biosciences of California, Inc., a leading provider of high-quality, long-read sequencing platforms, announced that it has signed a definitive merger agreement under which it will acquire Omniome, a San Diego-based company developing a highly differentiated, proprietary short-read sequencing platform capable of delivering high accuracy.

• Pacific Biosciences and Invitae Announce Intent to Expand Collaboration

  7/20/2021

  Pacific Biosciences of California, Inc., a leading provider of high-quality, long-read sequencing platforms, and Invitae Corporation, a leading medical genetics company, announced an intent to expand their multi-year collaboration to develop a production-scale high-throughput HiFi sequencing platform to include the sequencing technology developed by Omniome, Inc.